Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

Conditions

• Parkinson Disease

Eligibility Criteria

Sex

ALL

Age

40 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Lenrispodun — DRUG
  Lenrispodun 30 mg tablets administered orally, once daily.
• Placebo — DRUG
  Matching tablets administered orally, once daily.

Study Details

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.

Key Dates

First listed

Mar 13, 2023

Start date

Mar 13, 2023

Status verified

May 2026

Primary completion

Oct 28, 2025

Completion

Nov 4, 2025

Study Design

Enrollment

79 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Lenrispodun 30 mg
  Lenrispodun 30 mg tablets administered orally, once-daily.
• Placebo Comparator: Placebo
  Matching tablets administered orally, once daily.

Primary Outcome Measure

Hauser Diary [ Time Frame: Day 29 ]

Locations (35)

Find similar trials in Phoenix, AZ

Related Studies

• Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
  Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee
• Natural History Study of Synucleinopathies
  Recruiting · NYU Langone Health · Boston, Massachusetts
• Effects of Stimulation Patterns of Deep Brain Stimulation
  Enrolling By Invitation · Duke University · Gainesville, Florida
• Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
  PHASE1 · Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee